- Home
- JLS vs KLRS Comparison
JLS vs KLRS Comparison
Compare JLS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | KLRS |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 92.8M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JLS | KLRS |
|---|---|---|
| Price | $16.15 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 17.1K | ★ 52.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $3.02 |
| 52 Week High | $19.03 | $11.88 |
Technical Indicators
Market Signals| Indicator | JLS | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 18.12 | 30.10 |
| Support Level | N/A | $3.03 |
| Resistance Level | $18.66 | $4.37 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 0.00 | 9.89 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.